查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1822608

子宮內膜異位症治療市場機會、成長動力、產業趨勢分析及 2025 - 2034 年預測

Endometriosis Treatment Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2025 - 2034
出版日期: | 出版商: Global Market Insights Inc. | 英文 107 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

全球子宮內膜異位症治療市場規模預計在2024年達到17億美元，預計到2034年將以13.1%的複合年成長率成長，達到56億美元，這得益於人們認知度的提高、醫療技術的進步以及醫療服務可及性的改善。加強教育和早期診斷工作正在幫助更多患者在早期階段尋求醫療干預，從而刺激對有效治療方案的需求。醫療保健提供者正專注於綜合管理策略，這些策略不僅能立即緩解症狀，還能改善長期健康。政府措施和倡導團體在消除對子宮內膜異位症的偏見方面發揮關鍵作用，鼓勵更多女性尋求治療方案。研發投入的不斷增加也有助於擴大治療選擇，製藥公司正在探索創新療法以增強患者護理。

子宮內膜異位症治療市場 - IMG1

醫療保健支出的增加和保險覆蓋範圍的擴大使得子宮內膜異位症的治療更加便捷，使更多患者能夠及時獲得醫療救治。隨著相關宣傳活動不斷強調子宮內膜異位症未得到治療的長期影響，越來越多的患者正在尋求專科治療。對非侵入性治療方案的需求激增，尤其是在尋求手術介入替代方案的年輕患者中。醫療保健專業人員正在努力整合個人化治療方法，以滿足患者的個人化需求，進一步推動市場發展。

市場範圍
起始年份 2024
預測年份 2025-2034
起始值 17億美元
預測值 56億美元
複合年成長率 13.1%

按疾病類型分類，市場細分為不同類型，其中淺層性腹膜子宮內膜異位症在2024年佔據41.3%的主導佔有率。這種疾病的特徵是腹膜表面出現病變，比深層子宮內膜異位症更廣泛、更容易辨識。因此，這種疾病的診斷率更高，從而可以更快地進行醫療干預，並增加針對此類疾病的治療需求。表淺性腹膜子宮內膜異位症的早期發現和治療能力使其成為市場中最常見的疾病類型。

子宮內膜異位症的治療方案主要分為荷爾蒙療法和疼痛管理，其中荷爾蒙療法在2024年的收入為8.029億美元。醫生通常會開立避孕藥、黃體素和荷爾蒙調節藥物來緩解骨盆腔疼痛和月經過多等症狀。這些治療方法因其有效性、易於給藥以及能夠改善患者生活品質而越來越受歡迎。越來越多的人選擇荷爾蒙療法，因為它們無需侵入性手術即可緩解症狀。

2024年，美國子宮內膜異位症治療市場規模達5.821億美元，這得益於公共衛生計劃和宣傳活動的持續推進。致力於普及子宮內膜異位症的症狀和影響，鼓勵患者做出積極的醫療保健決策，並減少了人們對該疾病的偏見。醫學研究的進步、對生殖健康的日益關注以及專科醫療服務的普及，進一步加速了市場擴張。隨著對創新治療方案的需求持續成長，製藥公司和醫療保健提供者正致力於透過更先進、更有針對性的治療方法來改善患者的治療效果。

目錄

第1章：方法論與範圍

第2章：執行摘要

第3章：行業洞察

  • 產業生態系統分析
  • 產業衝擊力
    • 成長動力
      • 子宮內膜異位症的盛行率和認知度不斷上升
      • 診斷技術的進步
      • 增加政府資金和舉措
    • 產業陷阱與挑戰
      • 先進治療成本高
    • 市場機會
      • 非荷爾蒙療法的發展
      • 新興市場的擴張
  • 成長潛力分析
  • 監管格局
  • 技術進步
    • 當前的技術趨勢
    • 新興技術
  • 未來市場趨勢
  • 差距分析
  • 管道分析
  • 波特的分析
  • PESTEL分析

第4章：競爭格局

  • 介紹
  • 公司市佔率分析
  • 公司矩陣分析
  • 主要市場參與者的競爭分析
  • 競爭定位矩陣
  • 關鍵進展
    • 併購
    • 夥伴關係與合作
    • 新產品發布
    • 擴張計劃

第5章：市場估計與預測：按疾病類型，2021 - 2034 年

  • 主要趨勢
  • 表淺腹膜子宮內膜異位症
  • 卵巢子宮內膜異位症
  • 深部浸潤型子宮內膜異位症
  • 其他疾病

第6章：市場估計與預測：依治療類型，2021 - 2034

  • 主要趨勢
  • 荷爾蒙療法
  • 止痛藥

第7章：市場估計與預測：按藥物類別，2021 - 2034 年

  • 主要趨勢
  • 促性腺激素釋放激素
  • 非類固醇抗發炎藥
  • 口服避孕藥
  • 其他藥物類別

第 8 章：市場估計與預測：按管理路線，2021 年至 2034 年

  • 主要趨勢
  • 口服
  • 注射劑
  • 其他給藥途徑

第9章：市場估計與預測：按配銷通路，2021 - 2034 年

  • 主要趨勢
  • 醫院藥房
  • 零售藥局
  • 網路藥局

第 10 章：市場估計與預測：按地區，2021 年至 2034 年

  • 主要趨勢
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 西班牙
    • 義大利
    • 荷蘭
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：公司簡介

  • AbbVie
  • AstraZeneca
  • Bayer
  • Debiopharm
  • Gedeon Richter
  • Kissei Pharmaceutical
  • Pfizer
  • Sanofi
  • Teva Pharmaceutical
  • Zydus
簡介目錄
Product Code: 13210

The Global Endometriosis Treatment Market, valued at USD 1.7 billion in 2024 and is estimated to grow at a CAGR of 13.1% to reach USD 5.6 billion by 2034, driven by rising awareness, advances in medical treatments, and improved healthcare accessibility. Increased education and early diagnosis efforts are helping more individuals seek medical intervention at earlier stages, boosting demand for effective therapeutic solutions. Healthcare providers are focusing on comprehensive management strategies that not only address immediate symptom relief but also improve long-term health outcomes. Government initiatives and advocacy groups are playing a critical role in destigmatizing the condition, encouraging more women to pursue treatment options. The growing investment in research and development is also contributing to the expansion of treatment choices, with pharmaceutical companies exploring innovative therapies to enhance patient care.

Endometriosis Treatment Market - IMG1

Rising healthcare expenditure and improved insurance coverage have made endometriosis treatments more accessible, allowing more patients to receive timely medical attention. As awareness campaigns continue to highlight the long-term impact of untreated endometriosis, an increasing number of patients are seeking specialized care. The demand for non-invasive treatment options has surged, particularly among younger patients looking for alternatives to surgical interventions. Healthcare professionals are working to integrate personalized treatment approaches that cater to individual patient needs, further driving the market forward.

Market Scope
Start Year2024
Forecast Year2025-2034
Start Value$1.7 Billion
Forecast Value$5.6 Billion
CAGR13.1%

By disease type, the market is segmented into different forms, with the superficial peritoneal endometriosis segment holding a dominant 41.3% share in 2024. This form of the condition, characterized by lesions on the peritoneal surface, is widespread and more easily identifiable than deeper forms of endometriosis. As a result, it is diagnosed more frequently, leading to quicker medical intervention and higher demand for treatments targeting this type. The ability to detect and manage superficial peritoneal endometriosis early has positioned it as the most prevalent segment within the market.

Endometriosis treatment options are primarily divided into hormone therapy and pain management, with hormone therapy generating USD 802.9 million in 2024. Physicians commonly prescribe contraceptives, progestins, and hormone-modulating drugs to alleviate symptoms such as pelvic pain and excessive menstrual bleeding. These treatments are gaining popularity due to their effectiveness, ease of administration, and ability to improve patients' quality of life. More individuals are opting for hormone-based therapies as they provide symptom relief without the need for invasive procedures.

The United States endometriosis treatment market accounted for USD 582.1 million in 2024, fueled by increasing public health initiatives and awareness campaigns. Efforts to educate individuals about the symptoms and implications of endometriosis have encouraged proactive healthcare decisions and reduced stigma surrounding the condition. Advancements in medical research, a stronger focus on reproductive health, and improved access to specialized healthcare services are further accelerating market expansion. As demand for innovative treatment solutions continues to grow, pharmaceutical companies and healthcare providers are working to enhance patient outcomes through more advanced and targeted therapeutic approaches.

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market scope and definition
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Data mining sources
    • 1.3.1 Global
    • 1.3.2 Regional/Country
  • 1.4 Base estimates and calculations
    • 1.4.1 Base year calculation
    • 1.4.2 Key trends for market estimation
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
  • 1.6 Forecast model
  • 1.7 Research assumptions and limitations

Chapter 2 Executive Summary

  • 2.1 Industry 3600 synopsis
  • 2.2 Key market trends
    • 2.2.1 Regional trends
    • 2.2.2 Disease type trends
    • 2.2.3 Treatment type trends
    • 2.2.4 Drug class trends
    • 2.2.5 Route of administration trends
    • 2.2.6 Distribution channel trends
  • 2.3 CXO perspectives: Strategic imperatives
    • 2.3.1 Key decision points for industry executives
    • 2.3.2 Critical success factors for market players
  • 2.4 Future outlook and strategic recommendations

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Rising prevalence and awareness of endometriosis
      • 3.2.1.2 Advancement in diagnostic techniques
      • 3.2.1.3 Increased government funding and initiatives
    • 3.2.2 Industry pitfalls and challenges
      • 3.2.2.1 High cost of advanced treatment
    • 3.2.3 Market opportunities
      • 3.2.3.1 Development of non-hormonal therapies
      • 3.2.3.2 Expansion in emerging markets
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 North America
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
    • 3.4.4 Latin America
    • 3.4.5 Middle East and Africa
  • 3.5 Technological advancements
    • 3.5.1 Current technological trends
    • 3.5.2 Emerging technologies
  • 3.6 Future market trends
  • 3.7 Gap analysis
  • 3.8 Pipeline analysis
  • 3.9 Porter's analysis
  • 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Key developments
    • 4.6.1 Mergers & acquisitions
    • 4.6.2 Partnerships & collaborations
    • 4.6.3 New product launches
    • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

  • 5.1 Key trends
  • 5.2 Superficial peritoneal endometriosis
  • 5.3 Ovarian endometriomas
  • 5.4 Deep infiltrating endometriosis
  • 5.5 Other diseases

Chapter 6 Market Estimates and Forecast, By Treatment Type, 2021 - 2034 ($ Mn)

  • 6.1 Key trends
  • 6.2 Hormone therapy
  • 6.3 Pain medication

Chapter 7 Market Estimates and Forecast, By Drug Class, 2021 - 2034 ($ Mn)

  • 7.1 Key trends
  • 7.2 Gonadotropin-releasing hormone
  • 7.3 NSAIDs
  • 7.4 Oral contraceptive
  • 7.5 Other drug classes

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

  • 8.1 Key trends
  • 8.2 Oral
  • 8.3 Injectable
  • 8.4 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2034 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Argentina
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE

Chapter 11 Company Profiles

  • 11.1 AbbVie
  • 11.2 AstraZeneca
  • 11.3 Bayer
  • 11.4 Debiopharm
  • 11.5 Gedeon Richter
  • 11.6 Kissei Pharmaceutical
  • 11.7 Pfizer
  • 11.8 Sanofi
  • 11.9 Teva Pharmaceutical
  • 11.10 Zydus